Cargando…
Glycomimetics for the inhibition and modulation of lectins
Carbohydrates are essential mediators of many processes in health and disease. They regulate self-/non-self- discrimination, are key elements of cellular communication, cancer, infection and inflammation, and determine protein folding, function and life-times. Moreover, they are integral to the cell...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243309/ https://www.ncbi.nlm.nih.gov/pubmed/37232696 http://dx.doi.org/10.1039/d2cs00954d |
_version_ | 1785054399547047936 |
---|---|
author | Leusmann, Steffen Ménová, Petra Shanin, Elena Titz, Alexander Rademacher, Christoph |
author_facet | Leusmann, Steffen Ménová, Petra Shanin, Elena Titz, Alexander Rademacher, Christoph |
author_sort | Leusmann, Steffen |
collection | PubMed |
description | Carbohydrates are essential mediators of many processes in health and disease. They regulate self-/non-self- discrimination, are key elements of cellular communication, cancer, infection and inflammation, and determine protein folding, function and life-times. Moreover, they are integral to the cellular envelope for microorganisms and participate in biofilm formation. These diverse functions of carbohydrates are mediated by carbohydrate-binding proteins, lectins, and the more the knowledge about the biology of these proteins is advancing, the more interfering with carbohydrate recognition becomes a viable option for the development of novel therapeutics. In this respect, small molecules mimicking this recognition process become more and more available either as tools for fostering our basic understanding of glycobiology or as therapeutics. In this review, we outline the general design principles of glycomimetic inhibitors (Section 2). This section is then followed by highlighting three approaches to interfere with lectin function, i.e. with carbohydrate-derived glycomimetics (Section 3.1), novel glycomimetic scaffolds (Section 3.2) and allosteric modulators (Section 3.3). We summarize recent advances in design and application of glycomimetics for various classes of lectins of mammalian, viral and bacterial origin. Besides highlighting design principles in general, we showcase defined cases in which glycomimetics have been advanced to clinical trials or marketed. Additionally, emerging applications of glycomimetics for targeted protein degradation and targeted delivery purposes are reviewed in Section 4. |
format | Online Article Text |
id | pubmed-10243309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-102433092023-06-07 Glycomimetics for the inhibition and modulation of lectins Leusmann, Steffen Ménová, Petra Shanin, Elena Titz, Alexander Rademacher, Christoph Chem Soc Rev Chemistry Carbohydrates are essential mediators of many processes in health and disease. They regulate self-/non-self- discrimination, are key elements of cellular communication, cancer, infection and inflammation, and determine protein folding, function and life-times. Moreover, they are integral to the cellular envelope for microorganisms and participate in biofilm formation. These diverse functions of carbohydrates are mediated by carbohydrate-binding proteins, lectins, and the more the knowledge about the biology of these proteins is advancing, the more interfering with carbohydrate recognition becomes a viable option for the development of novel therapeutics. In this respect, small molecules mimicking this recognition process become more and more available either as tools for fostering our basic understanding of glycobiology or as therapeutics. In this review, we outline the general design principles of glycomimetic inhibitors (Section 2). This section is then followed by highlighting three approaches to interfere with lectin function, i.e. with carbohydrate-derived glycomimetics (Section 3.1), novel glycomimetic scaffolds (Section 3.2) and allosteric modulators (Section 3.3). We summarize recent advances in design and application of glycomimetics for various classes of lectins of mammalian, viral and bacterial origin. Besides highlighting design principles in general, we showcase defined cases in which glycomimetics have been advanced to clinical trials or marketed. Additionally, emerging applications of glycomimetics for targeted protein degradation and targeted delivery purposes are reviewed in Section 4. The Royal Society of Chemistry 2023-05-26 /pmc/articles/PMC10243309/ /pubmed/37232696 http://dx.doi.org/10.1039/d2cs00954d Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Chemistry Leusmann, Steffen Ménová, Petra Shanin, Elena Titz, Alexander Rademacher, Christoph Glycomimetics for the inhibition and modulation of lectins |
title | Glycomimetics for the inhibition and modulation of lectins |
title_full | Glycomimetics for the inhibition and modulation of lectins |
title_fullStr | Glycomimetics for the inhibition and modulation of lectins |
title_full_unstemmed | Glycomimetics for the inhibition and modulation of lectins |
title_short | Glycomimetics for the inhibition and modulation of lectins |
title_sort | glycomimetics for the inhibition and modulation of lectins |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243309/ https://www.ncbi.nlm.nih.gov/pubmed/37232696 http://dx.doi.org/10.1039/d2cs00954d |
work_keys_str_mv | AT leusmannsteffen glycomimeticsfortheinhibitionandmodulationoflectins AT menovapetra glycomimeticsfortheinhibitionandmodulationoflectins AT shaninelena glycomimeticsfortheinhibitionandmodulationoflectins AT titzalexander glycomimeticsfortheinhibitionandmodulationoflectins AT rademacherchristoph glycomimeticsfortheinhibitionandmodulationoflectins |